Skip to main content
RGEN logo

Repligen Corporation (RGEN) Stock: Price, Forecast & Analyst Target

Repligen Corporation (RGEN) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $170.29 (-1.38%), as of the Nov 19, 2026 trading session; market cap $10.9B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 12.63× (cash as of Sep 30, 2026) · expected results Feb 23, 2027

$170.29 −$2.38 (-1.38%) Market Cap $10.9B

Repligen Corporation · RGEN · NASDAQ · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Repligen supplies the filtration, chromatography, protein and process-analytics tools used to develop and manufacture biological drugs; it is an enabling-technology vendor, not a drug developer. Its case depends on whether rising demand, particularly for OPUS chromatography products, can outpace the operating costs accompanying that growth.

Price as of Nov 19, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Repligen (RGEN)

Strong
Business Quality Solid (68)
Financial Safety Fortress (82)
Valuation Rich (35)
Growth Durability Flat (46)
Momentum Surging (84)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but an expensive valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $209M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 7 of the last 8 reports
  • Altman Z 8.43 · Piotroski F 4

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RGEN (57 recorded, newest six shown)
RecordedScoreBand
74Strong
74Strong
74Strong
74Strong
71Strong
71Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$170.29
Change on the day-1.38%
52-week range$100.99–$198.87
Market capitalisation$10.9B—
Price / earnings (trailing)243.47
Shares traded on the day880.6K
Beta (volatility vs the S&P 500)1.12

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $103, high $190, latest $170. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $190 $103 high $190 Feb 24, 2026 · Earnings results · reported above the recorded estimate · close $1291May 5, 2026 · Earnings results · reported above the recorded estimate · close $1232Jul 28, 2026 · Earnings results · reported above the recorded estimate · close $1413Oct 27, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1774Oct 27, 2026 · Earnings results · reported above the recorded estimate · close $1775 Oct 17, 2025 Nov 19, 2026 · $170 $153Oct 17, 2025$149Oct 31, 2025$152Nov 14, 2025$171Nov 28, 2025$157Dec 12, 2025$166Dec 26, 2025$167Jan 9, 2026$162Jan 23, 2026$142Feb 6, 2026$136Feb 20, 2026$120Mar 6, 2026$114Mar 20, 2026$118Apr 2, 2026$131Apr 17, 2026$117May 1, 2026$103May 15, 2026$124May 29, 2026$131Jun 12, 2026$147Jun 26, 2026$144Jul 10, 2026$132Jul 24, 2026$164Aug 7, 2026$181Aug 21, 2026$168Sep 4, 2026$177Sep 18, 2026$182Oct 2, 2026$175Oct 16, 2026$177Oct 30, 2026$168Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • We expect CapEx spend to continue to be approximately 3% to 4% of 2026 revenue.

    Jason K. Garland · Statement from

  • For additional context, at the midpoint, our guidance assumes fourth quarter organic growth is in the range of our updated full year outlook.

    Jason K. Garland · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Repligen (RGEN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Strong
Valuation Weak
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 14, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Moderate
Debt/Equity Neutral
ROE Weak
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Repligen (RGEN), and what does it report?

Short answer · as of

Repligen sells bioprocessing components and integrated systems to biopharmaceutical companies, contract manufacturers, diagnostics businesses and laboratory researchers.

Its portfolio spans upstream cell-culture processing, downstream concentration and purification, affinity ligands, prepacked chromatography columns and in-process measurement systems.

Reported revenue overwhelmingly represents product sales. Filtration is the largest disclosed product family, followed by chromatography, while proteins and process analytics provide additional exposure to biologics production workflows.

2 · Latest results

What do the latest results show for Repligen (RGEN)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $209M.

Revenue extended an uninterrupted sequential rise and reached the highest level in the reported quarterly series. Gross profit also reached a series high, yet operating profit, net income and diluted earnings weakened again as selling and administrative expense remained elevated.

Management had linked its stronger chromatography outlook to OPUS traction and anticipated a richer chromatography mix, while also flagging additional investment. The latest accounts therefore show improving sales and gross economics without corresponding operating leverage, even as reported revenue and adjusted earnings again exceeded expectations.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$209.31M Sep 30, 2026
Latest quarter · R&D
$14.44M Sep 30, 2026
Latest quarter · SG&A
$83.59M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$29.55M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$209.31M$14.44M$83.59M−$29.55M
Jun 30, 2026$204.13M$14.42M$76.62M$11.93M
Mar 31, 2026$194.25M$14.46M$76.54M$17.99M
Dec 31, 2025$197.91M$12.18M$62.70M$18.56M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$209.31M Oct 27, 2026
Latest report · revenue estimate
$206.70M Oct 27, 2026
Latest report · revenue vs estimate
Above estimate Oct 27, 2026
Latest report · EPS vs estimate
Above estimate Oct 27, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 27, 2026$209.31M$206.70M$0.5300$0.4628
Jul 28, 2026$204.13M$201.59M$0.5400$0.4470
May 5, 2026$194.25M$192.05M$0.4800$0.3800
Feb 24, 2026$197.91M$192.94M$0.4900$0.4400
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$209M-$38M-$0.68 (diluted)
Q2 FY2026$204M$5M$0.09 (diluted)
Q1 FY2026$194M$8M$0.15 (diluted)
Q4 FY2025$198M$13M$0.23 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Repligen (RGEN)?

Short answer · as of

Cash and short-term investments were $862.98M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $43.10M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash and short-term investments exceed total debt, leaving Repligen in a net-cash position. Liquidity has risen across recent reporting periods, operating cash flow has remained positive throughout the available quarterly series, and capital spending has consumed only a modest share of that inflow.

The financial tension lies between balance-sheet resilience and modest current returns. Trailing margins and returns on capital remain subdued, while earnings and free-cash-flow yields are thin relative to the market value; failure to convert OPUS and broader bioprocessing demand into operating leverage would therefore expose the valuation.

Data-derived red flags

  • Negative return on equity (-0.6%) — the business is not currently generating profit on shareholder capital.
  • Rich valuation — a P/E of 243.47 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$43.10M Sep 30, 2026
Previous quarter · operating cash flow
$32.77M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$43.10M−$4.95M
Jun 30, 2026$32.77M−$5.10M
Mar 31, 2026$28.30M−$4.95M
Dec 31, 2025$25.70M−$8.66M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Repligen (RGEN)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

The scheduled earnings release should be tested against consensus expectations for another top-line advance but softer adjusted earnings. More important than another estimate beat is whether operating profit stabilizes while revenue continues rising.

OPUS demand, chromatography growth and the resulting product mix are the company-specific operating signals to follow. Cash conversion should corroborate any improvement: continued positive operating cash flow, restrained capital spending and further liquidity accumulation would show that growth is financing itself.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. This also means we will deliver a gain on our full year commitments and outpacing markets significantly.

    Olivier Loeillot ·

  2. Given recent trends, we plan to make some investments through the end of this year to support our expected growth in 2027. We will remain thoughtful about balancing investments in the business and expanding margins.

    Jason K. Garland ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Repligen compare with its peers?

Short answer

Repligen's score ranks tied for 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Repligen differs from a drug developer because it does not rely on the clinical success of a single therapeutic molecule. It sells tools consumed or deployed across customers’ process development and biological manufacturing operations.

Its breadth also distinguishes it from a narrowly focused laboratory-equipment supplier: filtration reaches upstream and downstream workflows, chromatography addresses purification, proteins supply affinity inputs, and process analytics measures production behavior. That breadth spreads demand across workflow steps, but filtration remains the largest disclosed product family and OPUS makes chromatography especially important to the present growth narrative.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Globus Medical, Inc. (GMED) Named competitor$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.37 Nov 19, 2026$5.48B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.41 Nov 19, 2026$5.06B81 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$175.76 Nov 19, 2026$4.40B73 5-pillar Nov 18, 2026
Stevanato Group S.p.A. (STVN) Same industry, near in market value$15.93 Nov 19, 2026$4.35B73 5-pillar Nov 18, 2026
Repligen (RGEN) — this page$170.29$10.9B71
Avantor, Inc. (AVTR) Same industry, near in market value$15.12 Nov 19, 2026$10.3B71 5-pillar Nov 18, 2026
Charles River Laboratories International, Inc. (CRL) Named competitor$327.93 Nov 19, 2026$15.7B70 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$163.40 Nov 19, 2026$6.48B61 5-pillar Nov 18, 2026
Baxter International Inc. (BAX) Named competitor$25.39 Nov 19, 2026$13.1B57 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$160.00 – $225.00
Consensus target
$198.00
Median target
$200.00

Consensus record · Captured .

Measured against a quoted price of $170.29 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 6, 2026

Transactions
24
Identified insiders
4
Purchases
0
Sales
8
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
535 Period end Sep 30, 2026
Previous quarter · holders
500 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC7,350,873
Blackrock, INC.5,726,731
United Capital Financial Advisors, LLC2,790,038
Vanguard Capital Management LLC2,442,741
Vanguard Portfolio Management LLC2,271,873

Tracked investors

Which of the 16 named investors we follow held RGEN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20260.33%$14.88MHeld, unchanged
Viking GlobalAndreas HalvorsenQ3 20260.31%$102.12MNew position
Bridgewater AssociatesFounded by Ray DalioQ3 20260.07%$17.13MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Repligen (RGEN)?

Read these with our analysis →

Common Questions About RGEN (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why does OPUS matter to Repligen?

OPUS comprises prepacked chromatography columns used in biologics purification and smaller formats used for process development and validation. Management cited OPUS traction when raising its chromatography outlook, making adoption of the platform a direct test of the current growth narrative.

Is Repligen a biologic drug developer?

Repligen supplies the manufacturing and process-development tools used by biologic drug producers. Its sales depend on customer activity across cell culture, filtration, purification and process analysis rather than approval of a Repligen-owned medicine.

Why is filtration important to Repligen?

Filtration is Repligen’s largest disclosed product family and spans upstream perfusion, downstream concentration, formulation, dialysis and single-use flow paths. This gives the company exposure to several stages of biological manufacturing rather than a single laboratory task.

Can Repligen finance its bioprocessing investment from operations?

Operating cash flow has remained positive across the available quarterly series and comfortably exceeded capital spending. Cash and short-term investments have also continued rising, indicating that recent investment has not eroded the liquidity cushion.

What is the RGEN stock price today?

The last price recorded for Repligen Corporation (RGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RGEN price target?

The analyst consensus price target for Repligen Corporation (RGEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 1. What is Repligen (RGEN), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Most recent periodic reports
  • 2. What do the latest results show for Repligen (RGEN)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Repligen (RGEN)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Repligen (RGEN)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 5. How does Repligen compare with its peers?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Why does OPUS matter to Repligen?: Business description; Management outlook — dated call excerpts
  • FAQ: Is Repligen a biologic drug developer?: Business description; Revenue by segment
  • FAQ: Why is filtration important to Repligen?: Revenue by segment; Business description
  • FAQ: Can Repligen finance its bioprocessing investment from operations?: Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.